Form 4: Paragon 28 Director Alf Grunwald Disposes of Shares in Merger with Zimmer Biomet

Director Alf Grunwald reports the disposal of Paragon 28 shares following the merger with Zimmer Biomet, receiving cash and contingent value rights.

Summary

• Alf Grunwald, a director of Paragon 28, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The filing is triggered by the merger between Paragon 28 and Zimmer Biomet, which became effective on April 21, 2025.
• As a result of the merger, Grunwald disposed of 51,935 shares of Paragon 28 common stock.
• Each share was converted into the right to receive $13.00 in cash and one contingent value right (CVR) potentially worth up to $1.00.
• The CVR is contingent upon the achievement of specified milestones outlined in the CVR Agreement.
• Grunwald also had restricted stock units that vested and were canceled, entitling him to the cash consideration and CVRs for each underlying share.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The merger provides shareholders with immediate cash and a potential future payout through the CVR. However, the CVR's value is uncertain.

Risks

• The contingent value right (CVR) payment is not guaranteed and depends on the achievement of specified milestones, introducing uncertainty.

Future Outlook

The future value of the CVR depends on Zimmer Biomet achieving the milestones specified in the CVR Agreement.

Industry Context

This merger reflects a trend of consolidation in the medical device industry, where larger companies acquire smaller, innovative firms to expand their product portfolios and market reach.

Comparison to Industry Standards

• Mergers in the medical device industry often involve a combination of upfront cash payments and contingent value rights (CVRs) to bridge valuation gaps and align the interests of both parties.
• Similar deals include Medtronic's acquisition of Mazor Robotics, which also included CVRs based on regulatory and commercial milestones.
• The $13.00 cash consideration per share is within the typical range for acquisitions of companies in Paragon 28's sector, but the ultimate value depends on the CVR payout.

Stakeholder Impact

• Shareholders receive $13.00 in cash per share and a CVR.
• Employees of Paragon 28 become part of Zimmer Biomet.

Key Dates

Keywords

Merger, Paragon 28, Zimmer Biomet, Form 4, Beneficial Ownership, Alf Grunwald, Contingent Value Right, CVR